Logo Logo
Group by: Item Type | Date
Number of items: 4.

Journal article

Behr, Jürgen ORCID logoORCID: https://orcid.org/0000-0002-9151-4829; Nathan, Steven D. ORCID logoORCID: https://orcid.org/0000-0002-6270-1617; Costabel, Ulrich ORCID logoORCID: https://orcid.org/0000-0003-2804-9511; Albera, Carlo ORCID logoORCID: https://orcid.org/0000-0002-0334-869X; Wuyts, Wim A.; Glassberg, Marilyn K. ORCID logoORCID: https://orcid.org/0000-0003-1990-6614; Haller, Harold; Alvaro, Giuseppe; Gilberg, Frank; Samara, Katerina und Lancaster, Lisa (2023): Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. In: Advances in Therapy, Vol. 40, No. 9: pp. 3937-3955 [PDF, 840kB]

Nathan, Steven D.; Costabel, Ulrich; Albera, Carlo; Behr, Jürgen; Wuyts, Wim A.; Kirchgaessler, Klaus-Uwe; Stauffer, John L.; Morgenthien, Elizabeth; Chou, Willis; Limb, Susan L. und Noble, Paul W. (2019): Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. In: Respiratory Medicine, Vol. 153: pp. 44-51

Behr, Jürgen; Crestani, Bruno; Wells, Athol; Kirchgässler, Klaus und Albera, Carlo (2017): N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply. In: Lancet Respiratory Medicine, Vol. 5, No. 1, E3-E3

Behr, Jürgen; Bendstrup, Elisabeth; Crestani, Bruno; Günther, Andreas; Olschewski, Horst; Sköld, C. Magnus; Wells, Athol; Wuyts, Wim; Koschel, Dirk; Kreuter, Michael; Wallaert, Benoit; Lin, Chin-Yu; Beck, Jürgen und Albera, Carlo (2016): Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. In: Lancet Respiratory Medicine, Vol. 4, No. 6: pp. 445-453

This list was generated on Sun Oct 6 00:46:54 2024 CEST.